Gilmore O’Neill, Editas Medicine CEO

Ed­i­tas re­ports ear­ly-stage da­ta from two pa­tients in sick­le cell dis­ease

One com­pa­ny is mov­ing for­ward in its bid to make a cell ther­a­py for sick­le cell dis­ease vi­able — and af­ter pre­vi­ous set­backs, in­clud­ing a hold ear­li­er this year, ex­ecs are tout­ing some re­al­ly ear­ly da­ta.

Ed­i­tas Med­i­cine an­nounced Tues­day morn­ing that it had pos­i­tive safe­ty and ef­fi­ca­cy da­ta from two pa­tients in a Phase I/II tri­al in­ves­ti­gat­ing ED­IT-301, a cell ther­a­py can­di­date that Ed­i­tas de­vel­oped. Safe­ty was mea­sured in both pa­tients, and ef­fi­ca­cy da­ta are from on­ly the first pa­tient dosed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.